Login / Signup

Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience.

Luca StingeniL BianchiE AntonelliE S CaroppoS M FerrucciM OrtoncelliG FabbrociniE NettisD SchenaMaddalena NapolitanoM GolaLaura BonzanoM RossiAnna Belloni FortinaAnna BalatoKetty PerisC FotiFabrizio GuarneriMarco RomanelliC PatrunoPaola SavoiaMaria-Concetta FargnoliF RussoEnzo ErrichettiT BianchelliL BianchiGiovanni PellacaniClaudio FelicianiA OffidaniM CorazzaG MicaliNicola MilanesiG MalaraA ChiricozziM TramontanaKatharina Hanselnull null
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Dupilumab in adolescent AD showed excellent effectiveness at week 16 with consistent improvement of all clinical scores. Moreover, dupilumab showed a good safety profile also in this COVID-19 pandemic era.
Keyphrases
  • atopic dermatitis
  • young adults
  • randomized controlled trial
  • systematic review
  • mental health
  • physical activity
  • clinical trial
  • early onset
  • study protocol
  • cross sectional
  • placebo controlled
  • drug induced